Forthcoming

Evaluation of Lupus Cases Related to TNF Inhibitors in Children

An Adverse Reaction of Anti-TNF Therapy


Abstract views: 104

Authors

  • Şeyma Türkmen University of Health Sciences Turkey, Ümraniye Training and Research Hospital Clinic of Pediatric Rheumatology, İstanbul, Turkey
  • Nelgin Gerenli University of Health Sciences Turkey, Ümraniye Training and Research Hospital, Clinic of Pediatric Gastroenterology, İstanbul, Turkey https://orcid.org/0000-0002-2395-163X
  • Betül Sözeri University of Health Sciences Turkey, Ümraniye Training and Research Hospital Clinic of Pediatric Rheumatology, İstanbul, Turkey https://orcid.org/0000-0002-5079-5644

DOI:

https://doi.org/10.4274/jpea.2022.226

Keywords:

Child, infliximab, systemic lupus erythematosus

Abstract

Systemic lupus erythematosus (SLE) due to anti-tumor necrosis factor (TNF) agents is a rare entity. We reported three cases who developed lupus-like syndrome while receiving infliximab therapy for various reasons. All cases demonstrated clinical and laboratory findings of SLE. And all of them needed treatment. We would like to emphasize that the risk of anti-TNF-alpha-induced lupus should be kept in mind in patients receiving anti-TNF therapy for any reason.

Author Biographies

Nelgin Gerenli, University of Health Sciences Turkey, Ümraniye Training and Research Hospital, Clinic of Pediatric Gastroenterology, İstanbul, Turkey

Department of Pediatric Gastroenterology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey

Betül Sözeri, University of Health Sciences Turkey, Ümraniye Training and Research Hospital Clinic of Pediatric Rheumatology, İstanbul, Turkey

Department of Pediatric Rheumatology, University of Health Sciences, Ümraniye Training and Research Hospital, Istanbul, Turkey

Downloads

Published

2023-07-21

How to Cite

Türkmen, Şeyma, Gerenli, N., & Sözeri, B. . (2023). Evaluation of Lupus Cases Related to TNF Inhibitors in Children: An Adverse Reaction of Anti-TNF Therapy. The Journal of Pediatric Academy. https://doi.org/10.4274/jpea.2022.226

Issue

2022: Accepted Articles

Section

Case Reports

License

Copyright (c) 2023 The Journal of Pediatric Academy

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The JPA offers users open access to reach all published articles freely within the framework of
NC-ND 4.0)” license.

Most read articles by the same author(s)